Senior Product Manager, Cala Health
Upstream
$160-190k
Bioelectronic medicine for chronic disease
Open for applications
Bioelectronic medicine for chronic disease
101-200 employees
Open for applications
$160-190k
101-200 employees
Company mission
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Jump to section
Company mission
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Our take
Essential Tremor is the most prevalent movement disorder in the world, with up to 5% of the global population affected by it. And yet, there were previously only two treatments: ongoing prescription drugs, which have side effects of drowsiness and nausea; or invasive surgery, which is costly and has risk of serious side effects.
Cala have developed a pioneering non-invasive treatment, which uses electrical stimulation from wearable device (it looks like a simple wristwatch) that monitors personal tremor levels and adapts its treatment to suit each patient. It is a world-leader in its field, and has revolutionized treatment for the 7 to 10 million Americans suffering from Essential Tremor.
Funding is focussed on expanding patient access, as well research into how to use their technology to treat Parkinson’s disease and other ailments.
Steph
Company Specialist at Welcome to the Jungle
Company values
- PROBLEM-SOLVING MINDSET: Building a new category of therapies requires breakthrough thinking. Intense curiosity drives us to discover and design life-changing solutions
- COLLABORATIVE CULTURE: Talented people thrive in passionate, inclusive teams where every team member matters. We inspire each other to make the impossible possible
- BUILDING THE FUTURE: We are delivering innovative therapies at the cutting-edge of technology and neuroscience. We believe non-invasive electrical medicines will change the face of healthcare
Funding (last 2 of 4 rounds)
Nov 2021
$77m
LATE VC
May 2019
$50m
SERIES C
Total funding: $148.3m
This company has top investors
Leadership
Kate Rosenbluth
(CSO & Board Director)Formerly a Consultant at Genentech, Scientist in Residence at Brainlab and Lecturer at Stanford.